Can't Afford Mounjaro Anymore — Your Practical Options

Step 1: Understand exactly what changed and why

The short answer is that Eli Lilly restructured Mounjaro's UK pricing from 1 September 2025. Before that date, the list price sat at roughly £122 per four-week pen regardless of dose. After it, prices became dose-dependent, with the 15mg pen reported at around £330. Private providers set their own final prices on top of that, so the figure you see varies, but almost everyone's bill went up. You can read more about how that played out on our Eli Lilly Mounjaro price increase page.

Knowing that this is a market-wide shift, not a single provider's decision, matters. It means hunting for a cheaper listing may not save as much as you'd hope, and some very low prices should prompt caution about supply chain legitimacy, the MHRA has consistently warned that medicines sold at prices far below the market norm are a red flag for counterfeits.

Start here, before anything else: get clear on the exact monthly figure you can sustain. That number shapes every decision below.

Step 2: Talk to your prescriber before you stop

This is the step most people skip, and it's the one our prescribers hear about most weeks, someone who quietly stopped because the cost felt impossible, then found their progress reversed faster than expected. Stopping tirzepatide abruptly isn't dangerous in the way stopping some medicines is, but appetite typically returns as the medicine clears your system, and weight regain can be significant without a plan in place.

A prescriber can do several things that stopping alone doesn't give you. They can review whether your current dose is the one you actually need, some people do well on a lower maintenance dose, which may cost less. They can map out a supervised pause with lifestyle support. They can assess whether switching to another licensed treatment makes clinical sense for you. The clinical team at nume reviews every treatment change before it happens, because a plan built around your health is more durable than one built around price alone.

If the medicine has stopped producing results regardless of cost, that's a separate conversation, and one worth having too. There's useful guidance on what to do if Mounjaro stops working that may be relevant here.

Step 3: Check whether you now qualify for NHS treatment

NHS access to tirzepatide is phased and tied to specific clinical criteria, but the cohorts are broadening. As of June 2025, adults with a BMI of 40 or above plus four or more of five qualifying conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes) became eligible. From around June 2026, that opened further to BMI 35–39.9 with four or more of those conditions. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

If you now meet those criteria, your GP practice may be able to prescribe under the new GP contract, though participation varies by practice. NHS England's weight-management injections guidance sets out the eligibility framework in full and is worth reading before you book a GP appointment. Waiting lists remain a reality in many areas, but knowing your position on the criteria is worth the conversation.

If you don't meet the NHS thresholds, or your practice isn't yet participating, private treatment remains the alternative. The reasons Mounjaro can be hard to access (both on the NHS and privately) are worth understanding so your expectations are realistic.

Step 4: Consider licensed alternatives with your prescriber

Mounjaro is not the only licensed weight-management injection in the UK. Semaglutide (Wegovy) is a once-weekly GLP-1 receptor agonist with a well-established evidence base; the STEP 1 trial, published in the New England Journal of Medicine, found an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. Pricing differs by dose and provider, and for some people on mid-range Mounjaro doses, the monthly cost of Wegovy may work out lower. A newer option (oral semaglutide tablets (Wegovy pill)) was approved by the MHRA in June 2026 for eligible adults, which adds another route to consider.

Whether any switch is appropriate depends on your health history, how you've responded to tirzepatide, and your prescriber's clinical view, so if you have been exploring Quanta tirzepatide as one of the options available to you, that is exactly the kind of choice to work through with a clinician rather than making alone. Our treatment options page gives an overview of what's available, and a free consultation is the right place to explore which fits your situation.

One more thing worth knowing: if cost is the reason you're considering stopping, it's also worth asking your provider directly about what's included in their price. Some services charge separately for consultations, prescriptions and aftercare, switching to one with a genuinely all-in price can reduce the real monthly figure without changing medicine at all. Side effects can also affect how sustainable treatment feels day to day, and if you have noticed that Mounjaro is disrupting your sleep, that is worth raising with your prescriber as part of the wider conversation. The cost of Mounjaro in the UK is unpacked in more detail if you want a fuller picture before your next clinical conversation.